GeneTx and Ultragenyx Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome
Go back to GeneTx and Ultragenyx Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 14.75 +0.24 (1.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.51 | 52 Week High | $117.12 | |||
| Open | $14.58 | 52 Week Low | $46.52 | |||
| Day High | $15.01 | P/E | N/A | |||
| Day Low | $14.28 | EPS | $-1.97 | |||
| Volume | 2,195,583 | |||||
